Journal articles: 'Platinum compounds'

1

Steggerda, J. J. "Platinum-Gold Cluster Compounds." Comments on Inorganic Chemistry 11, no. 2-3 (December 1990): 113–29. http://dx.doi.org/10.1080/02603599008035821.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hartmann, Jörg Thomas, and Hans-Peter Lipp. "Toxicity of platinum compounds." Expert Opinion on Pharmacotherapy 4, no. 6 (June 2003): 889–901. http://dx.doi.org/10.1517/14656566.4.6.889.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Martínez-Salvador, Sonia, Juan Forniés, Antonio Martín, and Babil Menjón. "Highly Trifluoromethylated Platinum Compounds." Chemistry - A European Journal 17, no. 29 (June 3, 2011): 8085–97. http://dx.doi.org/10.1002/chem.201100626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kasyanenko, Nina, Zhang Qiushi, Vladimir Bakulev, Petr Sokolov, and Konstantin Yakovlev. "DNA Conformational Changes Induced by Its Interaction with Binuclear Platinum Complexes in Solution Indicate the Molecular Mechanism of Platinum Binding." Polymers 14, no. 10 (May 17, 2022): 2044. http://dx.doi.org/10.3390/polym14102044.

Full text

Abstract:

Platinum anticancer drugs inhibit the division of cancer cells through a DNA binding mechanism. The bimetallic platinum compounds have a possibility for blocking DNA replication via the cross-linking of DNA functional groups at different distances. Many compounds with metals of the platinum group have been tested for possible antitumor activity. The main target of their biological action is a DNA molecule. A combined approach to the study of the interaction of DNA with biologically active compounds of this type is proposed. The capabilities of various methods (hydrodynamic, spectral, microscopy) in obtaining information on the type of binding of coordination compounds to DNA are compared. The analysis of DNA binding with platinum binuclear compounds containing pyrazine, tetrazole, 5- methyltetrazole, 3-propanediamine as bridging ligands in a solution was carried out with the methods of circular dichroism (CD), luminescent spectroscopy (LS), low gradient viscometry (LGV), flow birefringence (FB) and atomic force microscopy (AFM). The competitive binding of different platinum compounds to DNA and the analysis of platinum attachment to DNA after protonation of its nitrogen bases simply indicates the involvement of N7 guanine in binding. Fluorescent dye DAPI was also used to recognize the location of platinum compounds in DNA grooves. DNA conformational changes recorded by variations in persistent length, polyelectrolyte swelling, DNA secondary structure, and its stability clarify the molecular mechanism of the biological activity of platinum compounds.

APA, Harvard, Vancouver, ISO, and other styles

5

Crespo, Margarita. "Fluorine in Cyclometalated Platinum Compounds." Organometallics 31, no. 4 (October 20, 2011): 1216–34. http://dx.doi.org/10.1021/om200835g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mingos, D. Michael P., and Robert W. M. Wardle. "Homonuclear cluster compounds of platinum." Transition Metal Chemistry 10, no. 12 (1985): 441–59. http://dx.doi.org/10.1007/bf00620708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

MELNIK, M., and C. HOLLOWAY. "Stereochemistry of platinum coordination compounds." Coordination Chemistry Reviews 250, no. 17-18 (September 2006): 2261–70. http://dx.doi.org/10.1016/j.ccr.2006.02.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

M.J.C. "Platinum Compounds in Cancer Chemotherapy." Platinum Metals Review 29, no. 2 (April 1, 1985): 72. http://dx.doi.org/10.1595/003214085x2927272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Aris, Sheena M., and Nicholas P. Farrell. "Towards Antitumor Activetrans-Platinum Compounds." European Journal of Inorganic Chemistry 2009, no. 10 (April 2009): 1293–302. http://dx.doi.org/10.1002/ejic.200801118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Romano, Alberto, Michele Antonio Capozza, Stefano Mastrangelo, Palma Maurizi, Silvia Triarico, Rolando Rolesi, Giorgio Attinà, Anna Rita Fetoni, and Antonio Ruggiero. "Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer." Cancers 12, no. 5 (May 17, 2020): 1266. http://dx.doi.org/10.3390/cancers12051266.

Full text

Abstract:

Platinum compounds are a group of chemotherapeutic agents included in many pediatric and adult oncologic treatment protocols. The main platinum compounds are cisplatin, carboplatin, and oxaliplatin. Their use in clinical practice has greatly improved long-term survival of pediatric patients, but they also cause some toxic effects: ototoxicity, myelosuppression, nephrotoxicity, and neurotoxicity. Hearing damage is one of the main toxic effects of platinum compounds, and it derives from the degeneration of hair cells of the ear, which, not having self-renewal capacity, cannot reconstitute themselves. Hearing loss from platinum exposure is typically bilateral, sensorineural, and permanent, and it is caused by the same mechanisms with which platinum acts on neoplastic cells. According to available data from the literature, the optimal timing for the audiological test during and after treatment with platinum compounds is not well defined. Moreover, no substances capable of preventing the onset of hearing loss have been identified.

APA, Harvard, Vancouver, ISO, and other styles

11

Multhaupt, T. P., and S. K. Aggarwal. "Novel Second Generation Platinum Containing Antineoplastic Agents Ssp, Sap, and Poly-Plat and Their Effect on Glucose 6 Phosphate Dehydrogenase (Ec 1.1.1.49) in the Liver and Kidney of Male Wistar Rats." Microscopy and Microanalysis 3, S2 (August 1997): 57–58. http://dx.doi.org/10.1017/s1431927600007170.

Full text

Abstract:

Poly-(trans-l,2-diaminocyclohexane) platinumj-carboxyamylose (Poly-Plat); 5-SuIfosalicylato-trans-(l,2-diaminocyclohexane) platinum (SSP); and 4-Hydroxy-a-sulfonylphenylacetato (trans 1,2-diaminocyclohexane) platinum (II) (SAP) (Andrulis Pharmaceuticals, Bethesda, MD) are three novel second generation platinum containing antineoplastic compounds. Initial studies indicate that these agents are more effective in the treatment of cancer while at the same time less toxic to the organism as a whole than cisplatin (CDDP). The present study was undertaken to examine the effects of these new compounds on glucose-6-phosphate dehydrogenase (G-6-PDH) as compared to CDDP treated and normal kidney and liver tissues.Wistar rats (100-120g) were given intraperitoneal injections of CDDP (9 mg/ kg) and Poly-Plat, SSP and SAP (10 mg/ kg) over a 5 day period. On day 6 the animals were sacrificed and tissues (kidney and liver) were freeze sectioned (7 μm). Sections were incubated in media according to the accepted method specific for the G-6-PDH localization at a pH of 7.46 for 30 min.

APA, Harvard, Vancouver, ISO, and other styles

12

Dey, Sandip, and Vimal K. Jain. "Platinum Group Metal Chalcogenides." Platinum Metals Review 48, no. 1 (January 1, 2004): 16–29. http://dx.doi.org/10.1595/003214004x4811629.

Full text

Abstract:

Some salientfeatures of platinum group metal compounds with sulfur, selenium or tellurium, known as chalcogenides, primarily focusing on binary compounds, are described here. Their structural patterns are rationalised in terms of common structural systems. Some applications of these compounds in catalysis and materials science are described, and emerging trends in designing molecular precursors for the syntheses of these materials are highlighted.

APA, Harvard, Vancouver, ISO, and other styles

13

Ali, Mayyadah Mahmood, and Tavga Ahmed Aziz. "Toxic Effect of Platinum Compounds: Molecular Mechanisms of Toxicity." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 1 (October 30, 2021): 81–88. http://dx.doi.org/10.54133/ajms.v1i.32.

Full text

Abstract:

Despite their effectiveness as a crucial component of combination chemotherapy regimens against solid tumors, platinum compounds have many serious side effects that limit their use. This review article focuses on the various toxic effects of platinum compounds in cancer patients and the mechanisms of toxicity associated with each of these toxic effects. It also describes the future directions for developing novel platinum compounds, using both animal and human studies. The reference lists of relevant publications were included after searching the Google and Google Scholar databases, PubMed, and scientific journals. It focuses primarily on trials that were published between 2005 and 2020. Platinum-based medicines, as a soft nucleophile, can freely bind to peptides and proteins containing sulfur residues from thiol-containing amino acids like cysteine and methionine, as well as the antioxidant peptide glutathione. Platinum medicines, on the other hand, are primarily directed at nuclear DNA. Platinum medicines bind to normal cells as well as malignant cells, particularly those in fast growing tissues, causing a variety of dangerous side effects. Fast-growing tissues such as the mucous membranes of the mouth, throat, stomach, and intestines, bone marrow, and hair follicles can be damaged by cytotoxic chemotherapy drugs, resulting in gastrointestinal toxicities, myelosuppression, and hair loss. Platinum compounds also cause nephrotoxicity and hepatotoxicity, which are well-known side effects. Current platinum-based chemotherapy treatments have been restricted in the last decade, prompting a search for novel platinum-based medications with mechanisms of action distinct from those of existing chemotherapeutics.

APA, Harvard, Vancouver, ISO, and other styles

14

Sharutin, V., and E. Mekhanoshina. "Platinum nitrile compounds. Synthesis, structure, possibilities of practical application." Bulletin of the South Ural State University series "Chemistry" 15, no. 2 (2023): 5–34. http://dx.doi.org/10.14529/chem230201.

Full text

Abstract:

Methods of preparation, some reactions, structural features of platinum nitrile compounds and examples of their possible application are systematized and described based on analysis of the literature published mainly from 2020 to 2023. At the same time, attention is paid to the most effective approaches to obtaining platinum nitrile compounds. The formation reactions of platinum nitrile compounds are considered and information about their biological and catalytic activity is given.

APA, Harvard, Vancouver, ISO, and other styles

15

Igarashi, Kentaro, Norio Yamamoto, Toshiharu Shirai, Katsuhiro Hayashi, Hideji Nishida, Akihiko Takeuchi, Yoshikazu Tanzawa, et al. "Efficacy of newly developed platinum complexes against osteosarcoma, bone-targeting platinum, and proteasome inhibitory platinum." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10075. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10075.

Full text

Abstract:

10075 Background: Cisplatin is one of the most effective anti-cancer drugs available for the treatment of human solid tumors including osteosarcoma. As we had already reported, we have utilized caffeine in our chemotherapy protocol. And we achieved excellent clinical results. But effectiveness of cisplatin has been limited by side effects, and resistance. Here we developed two novel platinum compounds. 3Pt is trinuclear platinum complex bearing geminal bisphosphonate moieties, 1Pt is mononuclear platinum complex which has proteasome inhibitory activity. We performed comparative studies of our novel platinum compounds with osteosarcoma. Methods: Two novel platinum complexes were synthesized by Prof. Odani at school of pharmaceutical sciences of our university and cisplatin and caffeine were obtained from constructor. Three cell lines (MG63, 143B, and LM8) were used. Cell survival after a 72 hrs exposure to these compounds was assessed by WST-8 assay, and IC50 value was calculated for each compound. Apoptosis was assessed by DNA fragmentation and Annexin V-FITC/propidium iodine assay. Results: Each compound strongly caused concentration-dependent cytocidal effect. IC50 value of trinuclear compound is superior to cisplatin, and both complexes showed caffeine potentiation. Apoptosis induction and acetylation of histon H2AX were observed. In vivo, 1Pt showed almost same, 3Pt showed strong antitumor effect compared to cisplatin. Conclusions: Two novel platinum compounds that we developed showed strong ant-tumor effect in osteosarcoma in vitro and in vivo. As bisphosphonate has high affinity to calcium ions, 3Pt targets bone tissue and expected to reduce side effects at extraskeletal sites and to overcome the drug resistance. Proteasome inhibitory platinum compound has never been reported before, we will investigate its anti-tumor mechanism precisely.

APA, Harvard, Vancouver, ISO, and other styles

16

Chung, Tae Shin, Young Mee Na, Shin Won Kang, Ok-Sang Jung, and Young-A. Lee. "Facile generation of platinum(IV) compounds with mixed labile moieties. Hydrogen peroxide oxidation of platinum(II) to platinum(IV) compounds." Transition Metal Chemistry 30, no. 5 (August 2005): 541–45. http://dx.doi.org/10.1007/s11243-005-2653-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Soejima, Takashi, and Kei-ji Iwatsuki. "Innovative Use of Palladium Compounds To Selectively Detect Live Enterobacteriaceae in Milk by PCR." Applied and Environmental Microbiology 82, no. 23 (September 23, 2016): 6930–41. http://dx.doi.org/10.1128/aem.01613-16.

Full text

Abstract:

ABSTRACTEthidium monoazide and propidium monoazide (EMA and PMA) have been used in combination with PCR for more than a decade to facilitate the discrimination of live and dead bacteria (LD discrimination). These methods, however, require many laborious procedures, including the use of a darkroom. Here, we demonstrate an innovative use of palladium compounds involving lower limits of detection and quantification of targeted live cells, fewer laborious procedures, lower costs, and potentially higher-throughput analysis than the use of EMA and PMA. We have also recently reported platinum compounds for LD discrimination, but platinum compounds carry costs that are 3 times higher because of the requirement for much larger amounts for LD discrimination than palladium compounds. Palladium compounds can penetrate dead (compromised) but not live bacteria and can be chelated primarily by chromosomal DNA and cell wall transmembrane proteins, with small amounts of DNA-binding proteinsin vivo. The new mechanism for palladium compounds is obviously different from that of platinum compounds, which primarily target DNA. Combining palladium compounds with PCR (Pd-PCR) in water resulted in discrimination between live and deadEnterobacteriaceaebacteria that was much clearer than that seen with the PMA method. Pd-PCR correlated with reference plating or with the currently used PMA-PCR method for pasteurized milk, based on EN ISO 16140:2003 validation. Pd-PCR enabled us to specifically detect and assay viableEnterobacteriaceaecells at concentrations of 5 to 10 CFU/ml in milk while following U.S./EU regulations after a 4.5-h process in a typical laboratory exposed to natural or electric light, as specified by U.S./EU regulations.IMPORTANCEEthidium monoazide and propidium monoazide (EMA and PMA) facilitate the discrimination of live and dead bacteria (LD discrimination). These methods, however, require many laborious procedures, including the use of a darkroom. Here, we demonstrate an innovative use of palladium compounds involving fewer laborious procedures, lower costs, and potentially higher-throughput analysis than the use of EMA and PMA. We have also recently reported platinum compounds for LD discrimination, but platinum compounds carry costs that are 3 times higher because of the requirement for much larger amounts for LD discrimination than palladium compounds, which have also a novel reaction mechanism different from that of platinum compounds. In view of testing cost, palladium compounds are also very useful here compared with platinum compounds. Ultimately, the innovative Pd-PCR method may be also substituted for the currently used reference plating methods.

APA, Harvard, Vancouver, ISO, and other styles

18

Galanski, M., and B. K. Keppler. "Synthesis and Characterization of New Ethylenediamine Platinum(IV) Complexes Containing Lipophilic Carboxylate Ligands." Metal-Based Drugs 2, no. 1 (January 1, 1995): 57–63. http://dx.doi.org/10.1155/mbd.1995.57.

Full text

Abstract:

A series of new ethylenediamine (en) platinum(IV) complexes of the type Pt(IV)enX2A2 , with X2 = cyclobutane-1,1-dicarboxylato (CBDCA), dichloro or bis(decanoato) and A = acetato, dodecanoato, tetradecanoato, hexadecanoato, octadecanoato, adamantanecarboxylato (Ad) or 3α, 12α -diformoxy-5β-cholato (DFCA) were synthesized and characterized by elemental analysis, infrared and NMR (H1 and C13) spectroscopic techniques. Previous platinum(IV) compounds were usually restricted to trans-dihydroxo or trans-dichloro platinum(IV) complexes. Recently trans-dicarboxylato platinum(IV) complexes with mainly acetate, trifluoracetate or short-chain carboxylate groups (<11 carbons) in the axial position have been described in the literature[1,2,3]. In this paper we report on the synthesis and characterization of a new class of ethylenediamine platinum(IV) compounds that have high lipophilic long-chain carboxylate ligands either in the axial or equatorial position. The platinum(IV) compounds with the lipophilic trans-carboxylate ligands in the axial position were prepared by acylation of the trans-dihydroxo platinum(IV) species using an acyl halide in the presence of pyridine. In contrast to previous publications[1] the yields were excellent (up to 94%!).

APA, Harvard, Vancouver, ISO, and other styles

19

Ferrari, Giulia, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, and Diego Montagner. "Recent Advances on Pt-Based Compounds for Theranostic Applications." Molecules 29, no. 15 (July 23, 2024): 3453. http://dx.doi.org/10.3390/molecules29153453.

Full text

Abstract:

Since the discovery of cisplatin’s antitumoral activity and its approval as an anticancer drug, significant efforts have been made to enhance its physiological stability and anticancer efficacy and to reduce its side effects. With the rapid development of targeted and personalized therapies, and the promising theranostic approach, platinum drugs have found new opportunities in more sophisticated systems. Theranostic agents combine diagnostic and therapeutic moieties in one scaffold, enabling simultaneous disease monitoring, therapy delivery, response tracking, and treatment efficacy evaluation. In these systems, the platinum core serves as the therapeutic agent, while the functionalized ligand provides diagnostic tools using various imaging techniques. This review aims to highlight the significant role of platinum–based complexes in theranostic applications, and, to the best of our knowledge, this is the first focused contribution on this type of platinum compounds. This review presents a brief introduction to the development of platinum chemotherapeutic drugs, their limitations, and resistance mechanisms. It then describes recent advancements in integrating platinum complexes with diagnostic agents for both tumor treatment and monitoring. The main body is organized into three categories based on imaging techniques: fluorescence, positron emission tomography (PET), single–photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Finally, this review outlines promising strategies and future perspectives in this evolving field.

APA, Harvard, Vancouver, ISO, and other styles

20

Bulgakov, Roman A., Nina A. Kuznetsova, Olga V. Dolotova, Ludmila I. Solovieva, John Mack, Wadzanai J. U. Chidawanyika, Oleg L. Kaliya, and Tebello Nyokong. "Synthesis and photophysical properties of covalent conjugates of aqua platinum(II) and octacarboxy-substituted zinc phthalocyanine." Journal of Porphyrins and Phthalocyanines 16, no. 11 (October 22, 2012): 1217–24. http://dx.doi.org/10.1142/s1088424612501209.

Full text

Abstract:

New covalent conjugates of aqua platinum(II) and octacarboxy-substituted zinc phthalocyanine, bearing one, two, three and four aqua platinum moieties on the periphery of the Pc ligand have been synthesized and characterized. The effect of the stepwise introduction of the aqua platinums on the photophysical and photochemical properties of these compounds has been investigated in dimethylsulfoxide solution. It has been found that aqua platinum moieties have only a limited effect on the dynamics of the singlet and triplet excited states, on the ability to sensitize singlet oxygen formation and on the photostability. Each conjugate has a high singlet oxygen quantum yield (ΦΔ 0.51–0.62) and thus retains potential for use as a dual action anticancer drugs by acting as a sensitizer for PDT in addition to the likely chemotherapeutic effects of the Pt(II) complexes.

APA, Harvard, Vancouver, ISO, and other styles

21

Sharutin, V., and A. Zykova. "Organic platinum compounds containing one platinum–carbon bond. Synthesis, structure, possibilities of practical application." Bulletin of the South Ural State University series "Chemistry" 15, no. 3 (2023): 5–44. http://dx.doi.org/10.14529/chem230301.

Full text

Abstract:

The synthesis methods and structural features of organic platinum compounds containing one platinum–carbon bond have been systematized and described on the basis of analysis of the literature sources published mainly from 2020 to 2023. The discussion of the synthesis methods focuses on the most efficient approaches. Chemical properties of these platinum compounds, schemes of preparation and some mechanisms of reactions are presented. Information on biological activity, catalytic and photoluminescent properties is given.

APA, Harvard, Vancouver, ISO, and other styles

22

De Castro, Federica, Erik De Luca, Michele Benedetti, and Francesco Paolo Fanizzi. "Platinum compounds as potential antiviral agents." Coordination Chemistry Reviews 451 (January 2022): 214276. http://dx.doi.org/10.1016/j.ccr.2021.214276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ruggiero, Antonio, Giovanna Trombatore, Silvia Triarico, Roberta Arena, Pietro Ferrara, Maria Scalzone, Filomena Pierri, and Riccardo Riccardi. "Platinum compounds in children with cancer." Anti-Cancer Drugs 24, no. 10 (November 2013): 1007–19. http://dx.doi.org/10.1097/cad.0b013e3283650bda.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Chakraborty, Bimal K., Nupur Biswas, Kanakendu Choudhury, Rajat K. Neogy, and Das Sarma. "Antitumour Activity of Some Platinum Compounds." Chemotherapy 31, no. 1 (1985): 55–59. http://dx.doi.org/10.1159/000238314.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Muggia, Franco, and Nicholas Farrell. "Platinum coordination compounds in cancer chemotherapy." Critical Reviews in Oncology/Hematology 53, no. 1 (January 2005): 1–2. http://dx.doi.org/10.1016/j.critrevonc.2004.11.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Howell, B. A., R. Rashidianfar, J. R. Glass, B. J. Hutchinson, and D. A. Johnson. "Substitutedcatecholato(1,2-diaminocyclohexane)-platinum(II) compounds." Inorganica Chimica Acta 142, no. 2 (February 1988): 181–83. http://dx.doi.org/10.1016/s0020-1693(00)81554-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

van der Vijgh, W. J. F., and I. Klein. "Protein binding of five platinum compounds." Cancer Chemotherapy and Pharmacology 18, no. 2 (November 1986): 129–32. http://dx.doi.org/10.1007/bf00262281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Goodisman, Jerry, Douglas Hagrman, Kirk A. Tacka, and Abdul-Kader Souid. "Analysis of cytotoxicities of platinum compounds." Cancer Chemotherapy and Pharmacology 57, no. 2 (July 19, 2005): 257–67. http://dx.doi.org/10.1007/s00280-005-0041-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Reedijk, J., E. L. M. Lempers, A. F. Struik, and N. Boogaard. "Intracellular reactions of platinum antitumor compounds." Journal of Inorganic Biochemistry 36, no. 3-4 (August 1989): 282. http://dx.doi.org/10.1016/0162-0134(89)84397-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Gibson, D., H. Sheshinski, H. M. Greenblatt, A. Bino, and G. Shoham. "Adducts of platinum compounds with proteins." Journal of Inorganic Biochemistry 43, no. 2-3 (August 1991): 605. http://dx.doi.org/10.1016/0162-0134(91)84576-u.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bednarski, Patrick J., Ronald Gust, Thilo Spruss, Norbert Knebel, Angela Otto, Michael Farbel, Ronald Koop, Eggehard Holler, Ervin von Angerer, and Helmut Schonenberger. "Platinum compounds with estrogen receptor affinity." Cancer Treatment Reviews 17, no. 2-3 (September 1990): 221–31. http://dx.doi.org/10.1016/0305-7372(90)90052-h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bremi, Juliane, Margherita Fontana, Walter Caseri, and Paul Smith. "Polymeric Quasi-one-dimensional Platinum Compounds." Macromolecular Symposia 235, no. 1 (March 2006): 80–88. http://dx.doi.org/10.1002/masy.200650311.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Fetoni, A. R., A. Ruggiero, D. Lucidi, E. De Corso, B. Sergi, G. Conti, and G. Paludetti. "Audiological Monitoring in Children Treated with Platinum Chemotherapy." Audiology and Neurotology 21, no. 4 (2016): 203–11. http://dx.doi.org/10.1159/000442435.

Full text

Abstract:

Platinum compounds constitute the standard treatment for solid tumors in pediatric oncology. The purpose of this study is to assess the impact of platinum compounds in the development of ototoxicity in children following chemotherapy. This study included 160 patients treated with cisplatin and carboplatin for malignant solid diseases from 2007 to 2014. Their audiograms were classified according to the Boston SIOP ototoxicity scale. Twenty-five percent of the children treated with platinum compounds developed ototoxicity. The incidence of ototoxicity was correlated with the type of platinum derivative (i.e. cisplatin vs. carboplatin), coadministration of both drugs and concomitant cranial radiotherapy, but not with sex and age. Cumulative dose was correlated only with the cisplatin administration. Nine patients (8.6%) showed further progression of hearing impairment after the end of chemotherapy. The low rate of ototoxicity suggests the pivotal role of auditory monitoring in children treated with platinum compounds in order to be able to identify hearing loss at an early stage and to provide, jointly with pediatric oncologists, strategies to reduce further progression of cochlear toxicity.

APA, Harvard, Vancouver, ISO, and other styles

34

Szefler, Beata, and Przemysław Czeleń. "Docking of Platinum Compounds on Cube Rhombellane Functionalized Homeomorphs." Symmetry 12, no. 5 (May 6, 2020): 749. http://dx.doi.org/10.3390/sym12050749.

Full text

Abstract:

Platinum compounds are anti-cancer drugs and can bind to canonical purine bases, mainly guanine, found within double helical DNA. Platinum compounds can be transferred directly to pathologically altered sites in a specific and site-oriented manner by nanocarriers as potential nanocarriers for carboplatin. Two types of nanostructures were used as potential nanocarriers for carboplatin, the first were functionalized C60 fullerene molecules and the second were rhombellanes. The analyzed nanostructures show considerable symmetry, which affects the affinity of the studied nanocarriers and ligands. Thus symmetry of nanostructures affects the distribution of binding groups on their surface. After the docking procedure, analysis of structural properties revealed many interesting features. In all described cases, binding affinities of complexes of platinum compounds with functionalized fullerene C60 are higher compared with affinities of complexes of platinum compounds with rhombellane structures. All platinum compounds easily create complexes with functionalized fullerene C60, CID_16156307, and at the same time show the highest binding affinity. The binding affinities of lobaplatin and heptaplatin are higher compared with oxaliplatin and nedaplatin. The high value of binding affinity and equilibrium constant K is correlated with creation of strong and medium hydrogen bonds or is correlated with forming a hydrogen bond network. The performed investigations enabled finding nanocarriers for lobaplatin, heptaplatin, oxaliplatin and nedaplatin molecules.

APA, Harvard, Vancouver, ISO, and other styles

35

Frolov, V. M. "Platinum Metals Complex Catalysts for Liquid-Phase Hydrogenations." Platinum Metals Review 40, no. 1 (January 1, 1996): 8–18. http://dx.doi.org/10.1595/003214096x401818.

Full text

Abstract:

Results of the syntheses and applications of platinum metals complex catalysts, which are uniquely active for the liquid-phase hydrogenation of unsaturated organic compounds, such as olefins, dienes, acetylenes and aromatics, are described. The platinum metals complex catalysts are synthesised by the interaction between platinum metals compounds and aliphatic amines with sufficiently long alkyl groups (C8 and higher). Similarities are shown in the production of palladium-, platinum-, and rhodium-based catalysts, which involves the formation of hydride ligands, using the hydrogen atoms of the alkyl groups, and the specific catalytic behaviour of each metal is described. Examples of synergistic effects for these platinum group metal catalysts and some of their related systems are discussed.

APA, Harvard, Vancouver, ISO, and other styles

36

Turkson, James, Shumin Zhang, Jay Palmer, Heidi Kay, Joseph Stanko, Linda B. Mora, Said Sebti, Hua Yu, and Richard Jove. "Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity." Molecular Cancer Therapeutics 3, no. 12 (December 1, 2004): 1533–42. http://dx.doi.org/10.1158/1535-7163.1533.3.12.

Full text

Abstract:

Abstract DNA-alkylating agents that are platinum complexes induce apoptotic responses and have wide application in cancer therapy. The potential for platinum compounds to modulate signal transduction events that contribute to their therapeutic outcome has not been extensively examined. Among the signal transducer and activator of transcription (STAT) proteins, Stat3 activity is frequently up-regulated in many human tumors. Various lines of evidence have established a causal role for aberrant Stat3 activity in malignant transformation and provided validation for its targeting in the development of small-molecule inhibitors as novel cancer therapeutics. We report here that platinum-containing compounds disrupt Stat3 signaling and suppress its biological functions. The novel platinum (IV) compounds, CPA-1, CPA-7, and platinum (IV) tetrachloride block Stat3 activity in vitro at low micromolar concentrations. In malignant cells that harbor constitutively activated Stat3, CPA-1, CPA-7, and platinum (IV) tetrachloride inhibit cell growth and induce apoptosis in a manner that reflects the attenuation of persistent Stat3 activity. By contrast, cells that do not contain persistent Stat3 activity are marginally affected or are not affected by these compounds. Moreover, CPA-7 induces the regression of mouse CT26 colon tumor, which correlates with the abrogation of persistent Stat3 activity in tumors. Thus, the modulation of oncogenic signal transduction pathways, such as Stat3, may be one of the key molecular mechanisms for the antitumor effects of platinum (IV)–containing complexes.

APA, Harvard, Vancouver, ISO, and other styles

37

Yumuk, P. F., M. Teomete, F. Dane, D. Cabuk, G. Basaran, and N. S. Turhal. "Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e19055-e19055. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19055.

Full text

Abstract:

e19055 Background: Platinum compounds are the main component of the CT in NSCLC. Standard recommended doses of cisplatin/carboplatin is usually couldn’t be administered and dose reductions are necessary because of side effects. We aimed to determine the effect of dose reductions of platinums on outcome of stage IIIB/IV NSCLC. Methods: Data of 420 patients were retrospectively reviewed. A platinum analogue was used in combination with vinorelbine, gemcitabine, paclitaxel, docetaxel or etoposide as first line treatment in 85% patients. Cumulative platinum doses and dose reduction ratios compared to standard doses were calculated. Patients with decreased GFR were excluded from the analysis. Results: Median age was 60 years (range: 28-87), 79% of patients were male, 31% were 65 yearsold/older, 55% had PS of 0, and 27% had stage IIIB disease. Histological subtypes were squamous cell in 32%, adenocarcinoma in 34%, and NSCLC in 31%. Median dose of cisplatin used per cycle was 67mg/m2 and carboplatin was 287mg/m2. 51% of the patients received standard or less than 10% reducted doses of platinum, while dose reductions were 10–20% in 19%, 21–30% in 24% of patients, and more than 31% in 6%. Median overall survival (OS) was 11 months, 1- year and 2-year OS ratios were 56% and 25%, respectively. Median time to progression was 5 months; 1-year progression free survival ratio was 18%. Gender, age, histologic subtype, and treatment with lower dose of platinum didn’t have any statistically significant impact on survival in univariate analysis. Patients with PS of 0, no weight loss, stage IIIB disease, receiving combination CT with docetaxel-cisplatin, and having partial response to treatment lived significantly longer. On multivariate analysis weight loss, stage and type of response to treatment had an impact on OS. Conclusions: Using lower doses of platinum compounds in combination chemotherapy for stage IIIB/IV non-small cell lung cancer might not have a negative impact on survival and definitely have a better toxicity profile. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

38

Chotkowski, Maciej, Franciszek Miklaszewicz, and Andrzej Czerwinski. "The Platinum Catalyst Prepared from Platinum Carbonyls." Journal of New Materials for Electrochemical Systems 16, no. 4 (October 4, 2013): 263–67. http://dx.doi.org/10.14447/jnmes.v16i4.151.

Full text

Abstract:

Pt catalysts for methanol electro-oxidation were prepared by thermal decomposition of platinum carbonyls. [Pt3(CO)6]n2- were synthesized from inorganic platinum compounds (PtCl4 or (NH4)2PtCl4) in H2O-MeOH solutions using carbon monoxide as a reducing agent. The progress of the platinum carbonyls synthesis reaction and its performance were monitored using UV-Vis spectroscopy. The obtained results clearly indicate the possibility of using platinum carbonyls as intermediates for the synthesis of pure and finely divided platinum particles. The electrochemical tests of the platinum powders performed in the polymer-electrolyte low-temperature methanol fuel cells (DMFC) indicated good electrocatalytic properties of these materials.

APA, Harvard, Vancouver, ISO, and other styles

39

Coffetti, Giulia, Martina Moraschi, Giorgio Facchetti, and Isabella Rimoldi. "The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives." Molecules 28, no. 8 (April 12, 2023): 3407. http://dx.doi.org/10.3390/molecules28083407.

Full text

Abstract:

One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In particular, the research studies reported herein focus on the capability of some platinum-based anticancer agents to bypass resistance to chemotherapy, which is typical of well-known drugs such as cisplatin. Regarding platinum (II) complexes, this review deals with complexes in trans conformation; complexes containing bioactive ligands, as well as those that are differently charged, all experience a different reaction mechanism compared with cisplatin. Regarding platinum (IV) compounds, the focus was on complexes with biologically active ancillary ligands that exert a synergistic effect with platinum (II)-active complexes upon reduction, or those for which controllable activation can be realized thanks to intracellular stimuli.

APA, Harvard, Vancouver, ISO, and other styles

40

Ivanova, Stefka, Stefan Balkanski, Petar Atanasov, Maria Chaneva, Danka Obreshkova, Valentin Dimitrov, Krasimira Kazalukova, Lily Peikova, and Ognian Markov. "Antitumor and antioxidant activity of some metal complex compounds." Pharmacia 70, no. 2 (June 7, 2023): 375–82. http://dx.doi.org/10.3897/pharmacia.70.e105845.

Full text

Abstract:

In the last few years, interest in platinum drugs has increased. Successful treatment depends to a large extent on complex therapy and early diagnosis, which determines the great importance of knowledge of risk groups, clinical symptoms, and targeted use of diagnostic methods with biomarkers, biopsy and diagnostic imaging for early detection of the malignant process. Today, the mono-target strategy is being replaced by a poly-target therapy strategy, which achieves greater clinical efficacy in tumors with defined biomarkers. Key developments include elucidation of the mechanisms of tumor resistance to these drugs, the introduction of some new platinum- based agents and clinical combination studies using platinum drugs with resistance modulators or new drug-targeted drugs. Improved delivery of platinum drugs to tumors has been studied in early clinical trials using liposomal or copolymer-based products. Other investigated as anticancer agents are ruthenium and iron complexes. Ln(III) complexes have been shown to exert antioxidant activity.

APA, Harvard, Vancouver, ISO, and other styles

41

Galanski, M., B. K. Keppler, and Th Klenner. "Antitumor platinum compounds linked to amino phosphonic acids: Drug targeting with osteotropic platinum compounds against bone malignancies." Journal of Inorganic Biochemistry 59, no. 2-3 (August 1995): 212. http://dx.doi.org/10.1016/0162-0134(95)97318-k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Xiao, Xiao, James Trevor Oswald, Ting Wang, Weina Zhang, and Wenliang Li. "Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery." Current Medicinal Chemistry 27, no. 18 (June 3, 2020): 3055–78. http://dx.doi.org/10.2174/0929867325666181105115849.

Full text

Abstract:

As one of the leading and most important metal-based drugs, platinum-based pharmaceuticals are widely used in the treatment of solid malignancies. Despite significant side effects and acquired drug resistance have limited their clinical applications, platinum has shown strong inhibitory effects for a wide assortment of tumors. Drug delivery systems using emerging technologies such as liposomes, dendrimers, polymers, nanotubes and other nanocompositions, all show promise for the safe delivery of platinum-based compounds. Due to the specificity of nano-formulations; unwanted side-effects and drug resistance can be largely averted. In addition, combinational therapy has been shown to be an effective way to improve the efficacy of platinum based anti-tumor drugs. This review first introduces drug delivery systems used for platinum and combinational therapeutic delivery. Then we highlight some of the recent advances in the field of drug delivery for combinational therapy; specifically progress in leveraging the cytotoxic nature of platinum-based drugs, the combinational effect of other drugs with platinum, while evaluating the drug targeting, side effect reducing and sitespecific nature of nanotechnology-based delivery platforms.

APA, Harvard, Vancouver, ISO, and other styles

43

Sharutin, V., and A. Rybakova. "Organic platinum compounds containing two or more platinum–carbon bonds. Synthesis, structure, possibilities of practical application." Bulletin of the South Ural State University series "Chemistry" 15, no. 3 (2023): 45–88. http://dx.doi.org/10.14529/chem230302.

Full text

Abstract:

Methods of obtaining together with some reactions, and structural features of organic platinum compounds containing two or more platinum-carbon bonds, as well as examples of their possible use, have been systematized and described based on the analysis of the literature published mainly from 2020 to 2023, In discussion of the synthesis methods, the attention is mainly paid to the most efficient approach to obtain them. Formation reactions of organic platinum compounds are considered and information about their biological and catalytic activity is given.

APA, Harvard, Vancouver, ISO, and other styles

44

Muenchen, H. J., S. K. Aggarwal, H. K. Misra, and P. J. Andrulis. "Morphological and Histochemical Changes in Macrophage Activity After Novel Anti-Neoplastic Platinum Agents." Microscopy and Microanalysis 3, S2 (August 1997): 11–12. http://dx.doi.org/10.1017/s1431927600006942.

Full text

Abstract:

Poly-[(trans-1,2-diaminocyclohexane) platinumj-carboxyamylose (“poly-plat”), 5-sulfosalicylato-trans -(1,2-diaminocyclohexane) platinum (SSP), and 4-hydroxy-∝-sulfonylphenylacetato (trans 1,2-diaminocyclohexane) platinum (II) (SAP) are second generation analogs of cisplatin (CDDP) with higher efficacy and potency than cisplatin. This is particularly true of “poly-plat” which contains 1/5 the platinum of CDDP. In order to understand the mechanism of action of these compounds, isolated murine peritoneal macrophages in culture medium were treated with “poly-plat”, SSP, or SAP (5 μg/ml) for 2 h. Drug containing medium was then replaced with fresh medium and the cells were allowed to incubate at 37° C (5% CO2) for 24 h. Supernatants were collected at 0.5, 1, 2, and 24 h post-treatment for immunocytochemical analysis. Confocal microscopy studies demonstrated an increase in the number of lysosomes in the treated macrophages, but only “poly-plat” and SSP treated macrophages were stimulated to form cytoplasmic extensions at 2 h and 24 h.

APA, Harvard, Vancouver, ISO, and other styles

45

Melník, Milan, Peter Mikuš, and Clive Holloway. "Crystalographic and structural characterization of heterometallic platinum compounds. Part III: heterotrinuclear compounds." Open Chemistry 11, no. 6 (June 1, 2013): 827–900. http://dx.doi.org/10.2478/s11532-013-0226-3.

Full text

Abstract:

AbstractThis review article includes over three hundred and sixty heterotrinuclear platinum complexes of the composition Pt2M (205 examples), PtM2 (132 examples) and PtMM (24 examples). The heterometals include the non-transition and transition metals. Three metal atoms form a wide variability of frameworks: M3 triangular, dicapped M3 triangular, V shaped M3, M3 linear, five-, six- and seven- metallocycles and unique structures of which triangular and linear are the most common. This has led to a rich chemistry of platinum not only from variability of metals, but also from their framework and stereochemistry. The shortest Pt-M (non-transition) and Pt-M (transition) bonds are 2.315(1) Å for Pt-Ga and 2.4896(9) Å for Pt-Co. The shortest Pt-Pt bond distance is 2.581(1) Å. Two complexes exist in two isomeric forms and several others contain crystallographically independent molecules. All are typical examples of distortion isomerism. Correlations between structural parameters, heterometal and ligand donor atoms are developed and discussed.

APA, Harvard, Vancouver, ISO, and other styles

46

Bissinger, Herbert, and Wolfgang Beck. "Metallkomplexe mit biologisch wichtigen Liganden, XXXIX [1]. Platin(IV)-Komplexe mit α-Aminosäure-und Peptidestern; 15N-und 195Pt-NMR-Spektren von α-Aminosäuren-Platin-Komplexen / Metal Complexes with Biologically Important Ligands, XXXIX [1]. Platinum(IV) Complexes with α-Amino Acid Esters and Peptide Esters; 13N and 195Pt NMR Spectra of Platinum Complexes with α-Amino Acids." Zeitschrift für Naturforschung B 40, no. 4 (April 1, 1985): 507–11. http://dx.doi.org/10.1515/znb-1985-0412.

Full text

Abstract:

The platinum(IV) complexes PtX4L2 (X = Cl, Br; 2 X = oxalate; L = glyOEt, glyglyOEt, gly-cleuOEt; 2 L = metOEt) have been obtained by oxidative addition of halogenes to platinum(II) compounds PtX2L2. A high field shift of δ15N ( ∼ 50 ppm) is observed for the coordinated amino acid ligand of various platinum complexes, compared to the free ligand. Platinum(II) and platinum(IV) can be distinguished by their 195Pt NMR signals.

APA, Harvard, Vancouver, ISO, and other styles

47

Melník, Milan, Peter Mikuš, and Clive Eduard Holloway. "Platinum organometallic compounds: classification and analysis of crystallographic and structural data of monomeric five and higher coordinated." Reviews in Inorganic Chemistry 33, no. 1 (May 1, 2013): 13–103. http://dx.doi.org/10.1515/revic-2013-0001.

Full text

Abstract:

AbstractFour hundred and twenty monomeric organoplatinum compounds, in which platinum atoms are five- and higher coordinated, are analyzed. The platinum atoms are found in the oxidation states +2, +3 and +4. The Pt(II) compounds by far prevail. There are wide varieties of the inner coordination spheres about the platinum centers. The Pt(II) compounds are five-coordinated (trigonal bipyramidal and square pyramidal), six-coordinated (different degrees of distortion), seven-coordinated (pentagonal bipyramidal, piano stool) and sandwiched (PtC10). The Pt(III) compound is square-planar. The Pt(IV) compounds are six- and eight-coordinated. There are several relationships between the Pt-L bond distances, covalent radii of the coordinated atom/ligand, and metallocycles, which are discussed. The trans-effect plays an important role in the inner coordination spheres about the Pt centers, especially on the Pt-L bond distances.

APA, Harvard, Vancouver, ISO, and other styles

48

Ramstad, Tore, and J. Derek Woollins. "The platinum benzole acid blues ? a new class of blue platinum compounds." Transition Metal Chemistry 10, no. 4 (April 1985): 153–55. http://dx.doi.org/10.1007/bf00641588.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Bhowmik, Sanjukta Ray, Snigdha Gangopadhyay, and Pijush Kanti Gangopadhyay. "Platinum coordination compounds of thiosemicarbazide derivatives: a new class of platinum blues." Journal of Coordination Chemistry 58, no. 9 (June 15, 2005): 795–801. http://dx.doi.org/10.1080/00958970500110891.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sharutin, V. V., and A. R. Zykova. "Synthesis and Reactivity of Organometallic Platinum Compounds containing one platinum–carbon bond." Reviews and Advances in Chemistry 13, no. 2 (June 2023): 111–51. http://dx.doi.org/10.1134/s2634827623700228.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Platinum compounds'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles